Boliven Patents - US7179650: Compositions and uses for a novel cell-death-protecting protein

Join
today

Boliven PRO is more than just patent search

Build and save lists using the powerful Lists feature
Analyze and download your search results
Share patent search results with your clients

New to Patents? Find out more from CambridgeIP ®

US7179650: Compositions and uses for a novel cell-death-protecting protein

Filing Information

Inventor(s)	Edward T. H. Yeh ·
Assignee(s)	Board of Regents, the University of Texas System · View assignee updates
Attorney/Agent(s)	Fulbright & Jaworski LLP ·
Primary Examiner	Anne M. Wehbe′ ·
Application Number	US9484964
Filing date	01/18/2000
Issue date	02/20/2007
Predicted expiration date	11/04/2017
U.S. Classifications	435/455 · 435/320.1 · 435/325 ·
International Classifications	C12N1563 · C12N1574 · C12N500 ·
Kind Code	B1
Related U.S. Application Data	1.0 BACKGROUND OF THE INVENTION This application is a divisional of U.S. patent application Ser. No. 08/964,162, now abandoned, filed on Nov. 4, 1997, which is a continuing application of U.S. Provisional Application Ser. No. 60/030,302, filed Nov. 5, 1996, the content of which is specifically incorporated herein by reference in its entirety.

Abstract

Disclosed are compositions comprising a novel cell-death protecting protein, sentrin-1, and the gene which encodes it. Also disclosed are methods of making and using sentrin polypeptides and nucleic acid segments in various diagnostic and pharmaceutical applications. In a preferred embodiment, overexpression of sentrin-1 confers protection against both anti-Fas/APO-1 and TNF-induced apoptosis.

Independent Claims | See all claims (6)

1. A method of inhibiting apoptosis in a cell comprising providing, in vitro, the cell with a nucleic acid segment encoding a polypeptide comprising SEQ ID NO:2, wherein a Fas and/or TNFR1 mediated apoptosis pathway is inhibited in the cell.
4. A method of inhibiting apoptosis in a cell comprising providing, in vitro, the cell with a nucleic acid segment comprising at least SEQ ID NO:1, wherein a Fas and/or TNFR1 mediated apoptosis pathway is inhibited in the cell.

References Cited

U.S. Patent Documents

Document Number	Assignees	Inventors	Issue/Pub Date
US4196265	The Wistar Institute	Koprowski et al.	Apr 1980
US4554101	New York Blood Center, Inc.	Hopp	Nov 1985
US4683195	Cetus Corporation	Mullis et al.	Jul 1987
US4683202	Cetus Corporation	Mullis	Jul 1987
US4757011	E. I. Du Pont De Nemours and Company	Chaleff et al.	Jul 1988
US4769061	Calgene Inc.	Comai	Sep 1988
US4940835	Monsanto Company	Shah et al.	Jul 1990
US4965188	Cetus Corporation	Mullis et al.	Oct 1990
US4971908	Monsanto Company	Kishore et al.	Nov 1990
US5176995	Hoffmann-La Roche Inc.	Sninsky et al.	Jan 1993
US5384253	DeKalb Genetics Corporation	Krzyzek et al.	Jan 1995

Foreign Patent Documents

Document Number	Assignees	Inventors	Issue/Pub Date
WO199531544			Nov 1995

Other Publications

Orkin et. al.; Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy, 1995.*

Lieberthal et. al.; Mechanisms of apoptosis and its potential role in renal tubular epithelial cell injury, 1996, Invited Review : F477-F488.*

Lavin et. al.; Role of protein kinase activity in apoptosis, 1996, Experiential 52:979-994.*

Marshall; Gene Therapy's Growing Pains, 1995, Science, vol. 269: 1050-1055.*

Verma et. al.; Gene therapy- promises, problems and prospects, 1997, Nature vol. 389: 239-242.*

Boddy et al., “PIC 1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukemia”, Oncogene, 13:971-982, 1996.

Cenciaelli et al., “T cell antigen receptor ubiquitination is a consequence of receptor-mediated tyrosine kinase activation,” J. Biol. Chem., 271(15):8709-8713, 1996.

Chinnaiyan et al., “FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis,” Cell, 81:505-512, 1995.

Chinnaiyan et al., “FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis,” J. Biol. Chem., 271(9):4961-4965, 1996.

Chu et al., “A Fas-associated protein factor, FAF1, potentiates Fas-mediated apoptosis,” Proc. Natl. Acad. Sci. USA, 92:11894-11898, 1995.

Coux et al., “Structure and functions fo the 20S and 26S proteasomes,” Annu. Rev. Biochem., 65:801-847, 1996.

Darnay et al., “Identification of a protein kinase associated with cytoplasmic domain of the p60 tumor necrosis factor receptor,” J. Biol. Chem., 269(32):20299-20304, 1994.

Finley et al., “Inhibition of proteolysis and cell cycle progression in a multiubiquitination-deficient yeast mutant,” Mol. Cell. Biol., 14(8):5501-5509, 1994.

Görlich et al., “Nucleocytoplasmic transport,” Science, 271:1513-1518, 1996.

Göttlicher et al., “Interaction of the Ubc9 human homologue with c-Jun and with the glucocorticoid receptor,” Steroids, 61:257-262, 1996.

Hateboer et al., “mUBC9, a novel adenovirus E1A-interacting protein that complements a yeast cell cycle defect,” J. Biol. Chem., 271(42):25906-25911, 1996.

Hsu et al., “TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways,” Cell, 84:299-308, 1996a.

Hsu et al. “TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1,” Immunity, 4:387-396, 1996b.

Kamitani et al., “Characterization of NEED8, a developmentally down-regulated ubiquitin,” J. Biol. Chem., 272(45):28557-28562, 1997b.

Kamitani et al., “Preferenctial modification of nuclear proteins by a novel ubiquitin-like molecule,” J. Biol. Chem., 272(22):14001-14004, 1997.

Kho et al., “Degradation of E2A proteins through a ubiquitin-conjugating enzyme, UbcE2A,” J. Biol. Chem., 272(6):3845-3851, 1997.

Kischkel et al., “Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor,” EMBO J., 14(22):5579-5588, 1995.

Mannen et al., “Cloning and expression of human homolog HSMT3 to yeast SMT3 suppressor of MIF2 mutations in a centromere protein gene,” Biochem. Biophy. Res. Comm., 222:178-180, 1996.

Muzio et al., “FLICE, novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex,” Cell, 85:817-827, 1996.

Nuber et al., “Cloning of human ubiquitin-conjugating enzymes UbcH6 and UbcH7 (E2-F1) and characterization of their interaction with E6-AP and RSP5,” J. Biol. Chem., 271(5):2795-2800, 1996.

Saitoh et al., “RanBP2 associates with Ubc9p and a modified form of RanGAP1,” Proc. Natl. Acad. Sci. USA., 94:3736-3741, 1997.

Stanger et al., “RIP: a novel protein containing a death domain that interacts with Fas/APO-1 (CD95) in yeast and causes cell death,” Cell, 81:513-523, 1995.

Takayama et al., “Cloning and functional analysis of BAG-1: a novel Bcl-2-binding protein with anti-cell death activity,” Cell, 80:279-284, 1995.

Wang et al., “Molecular cloning of a cNDA and chromosome localization of the gene for human ubiquitin-conjugating enzyme 9,” J. Biol. Chem., 271(40):24811-24816, 1996.

Ayala et al., “Mendelain Genetics,” In: Modern Genetics, 2nd Edition, Menlo Park, California, Benjamin/Cummings Publishing Co., Inc., Chapter 2, p. 44, 1984.

Darnell et al., In: Molecular Cell Biology, Scientific American Books, New York, pp. 77-80 and 248-257, 1986.

Database GenBank on STN. US National Library of Medicine (Bethesda, MD, USA). GenBank Accession No. H98111, Hellier et al., “The WashU-Merck EST Project,” yx09d11.sl Homo sapiens cDNA clone 261237 3′. Dec. 12, 1995.

Database GenBank on STN. US National Library of Medicine (Bethesda, MD, USA). GenBank Accession No. H24103, Hellier et al., “The WashU-Merck EST Project,” ym50b07.rl Homo sapiens cDNA clone 51818 5′. Jul. 6, 1995.

International Search Report dated Mar. 11, 1998 (PCT/US97/20344)(UTFH:238P).

Shen et al., “UBL1, a human ubiquitin-like protein associating with human RAD51/RAD52 proteins,” Genomics, 36(2):271-279, 1996.

Matunis et al., “A novel ubiquitin-like modification modulates the partitioning of the ran-GTpase-activating protein Ran GAP1 between the Cytosol and the nuclear pore complex,” J. Cell Biol., 135(6):1457-1470, 1996.

Okura et al., “Protection against Fas/APO-1 and tumor necrosis factor-mediated cell death by a novel protein, Sentrin,” J. Immunol., 157(10):4277-4281, 1996.

Shen et al., “Associations of UBE21 with RAD52, UBL1, p. 53, and RAD51 proteins in a yeast two-hybrid systems,” Genomics, 37:183-186, 1996.

* cited by examiner

Referenced By

The current document is not referenced by other documents.

Patent Family

Document Number	Assignee	Inventors	Issue/Pub Date
CA2273185	UNIV TEXAS	YEH EDWARD T H	May 1998
EP0960126	BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM	YEH, Edward, T., H.	Dec 1999
US7179650	Board of Regents, the University of Texas System	Edward T. H. Yeh	Feb 2007